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Abstract The dissemination in the central nervous system
(CNS) is an uncommon but fatal complication occurring in
patients with diffuse large B-cell lymphoma (DLBCL).
Standard prophylaxis has been demonstrated to reduce CNS
relapse and improve survival rates. Intrathecal (IT) liposomal
cytarabine allows maintaining elevated drug levels in the ce-
rebrospinal fluid for an extended period of time. Data on the
efficacy and safety of liposomal cytarabine as CNS prophy-
laxis in patients with DLBCL are still insufficient. The objec-
tive of the present study was to evaluate the effectiveness and
safety of the prophylaxis with IT liposomal cytarabine in pre-
vention of CNS relapse in high-risk patients with DLBCL
who were included in a trial of first line systemic therapy with
6 cycles of dose-dense R-CHOP every 14 days. Twenty-four
(18.6 %) out of 129 patients were identified to have risk fac-
tors for CNS involvement, defined as follows: >30 % bone
marrow infiltration, testes infiltration, retroperitoneal mass
≥10 cm, Waldeyer ring, or bulky cervical nodes involvement.
Liposomal cytarabine (50 mg) was administered by lumbar
puncture the first day of the 1st, 2nd, and 6th cycle of R-
CHOP14 scheme. Among 70 IT infusions, grade 3–4 adverse
events reported were headache (one patient) and nausea/
vomiting (one patient). With a median follow-up of
40.1 months, no CNS involvement by DLBCL was observed
in any patient. In conclusion, IT liposomal cytarabine is safe,
feasible, and effective for CNS prophylaxis, causing few as-
sociated risks and little discomfort to patients with DLBCL.
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Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common
type of non-Hodgkin’s lymphoma in adults, presenting an
annual incidence estimated in 3–5 cases per 100,000 inhabi-
tants [1, 2]. The gold standard treatment for DLBCL includes
rituximab, cyclophosphamide, doxorubicin, vincristine, and
prednisone (R-CHOP) administered every 14 or 21 days,
achieving long-term disease-free survival in approximately
60 % of patients [3–6]. The dissemination in the central ner-
vous system (CNS) is an uncommon complication with an
incidence rate of about 5 %, but can rise up to 25% depending
on patient’s risk factors, such as elevated serum lactate dehy-
drogenase (LDH) or the implication of extranodal sites or
testes [7–14]. CNS involvement occurs early in the course of
the DLBCL (4.7–9.0 months from diagnosis) and is associat-
ed with poor outcomes since survival drops to 2–5 months.
Prophylaxis has been demonstrated to reduce CNS relapse
and improve survival rates [15, 16]. For this reason,
American and European guidelines recommend the perfor-
mance of a diagnostic lumbar puncture and the administration
of CNS prophylaxis for high-risk patients [17, 18]. Standard
strategy for the prophylaxis includes systemic chemotherapy
that crosses hematoencephalic barrier, intrathecal (IT) chemo-
therapy, radiation therapy, or their combination [19]. IT che-
motherapy has become the approach most frequently used
because acting directly in the cerebrospinal fluid (CSF) and
maintaining therapeutic drug concentrations [20, 21]. Main IT
regimens include methotrexate (MTX) or cytarabine.
Liposomal cytarabine, a sustained-release preparation of
cytarabine for IT administration, allows maintaining elevated
drug levels in the CSF for an extended period of time
(>14 days) [19, 22]. The efficacy and safety of liposomal
cytarabine have been demonstrated in Burkitt’s lymphoma,
acute lymphoblastic leukemia, and unclassifiable highly ag-
gressive B-cell lymphoma [23, 24]. However, data in patients
with DLBCL in prophylactic therapy are still insufficient.
The objective of the present study was to evaluate the ef-
fectiveness and safety of the CNS prophylaxis with IT liposo-
mal cytarabine in high-risk patients with DLBCL who were
included in a prospective trial of first line systemic therapy
with 6 cycles of dose-dense R-CHOP every 14 days.
Patient and methods
Study population
A single arm open label multicentre study conducted between
2006 and 2011 evaluated dose-dense R-CHOP every 14 days
in DLBCL patients (EudraCT identifier 2005-005110-20).
The criteria for inclusion were as follows: aged over 18, diag-
nosis of DLBCL [25], Eastern Cooperative Oncology Group
performance status (ECOG PS) 0–2, any International
Prognostic Index (IPI) if aged over 65, or IPI 0–2 (if under
65), B-cells positive for CD20, and the informed consent
signed. Among the exclusion criteria were pregnancy or
breastfeeding, central nervous system lymphoma, severe im-
pairment of the renal function, human immunodeficiency vi-
rus (HIV) infection, previous treatment for DLBCL, heart
failure (ejection fraction <40 %), severe psychiatric disorders,
and hypersensitivity to murine proteins or any other compo-
nent of the drug. The present study included a subset of pa-
tients who required CNS prophylaxis with liposomal
cytarabine (DepoCyt®) by presenting one or more of the fol-
lowing risk factors for CNS involvement (considered when
the trial was designed): > 30% bonemarrow infiltration, testes
infiltration, retroperitoneal mass ≥10 cm, Waldeyer ring in-
volvement, or bulky cervical nodes involvement.
Experimental procedure
R-CHOP was administered every 14 days for 6 cycles (R-
CHOP14): 375 mg/m2 rituximab iv on day 1 plus CHOP
chemotherapy regimen (750 mg/m2 cyclophosphamide iv+
50 mg/m2 adriamycin iv+1.4 mg/m2 vincristine iv (maximal
dose 2 mg), all on day 1 plus 100 mg oral prednisone on days
1–5). At day 2 of each cycle, 6 mg pegfilgrastim was admin-
istered subcutaneously. The tumor response, i.e., complete
remission (CR), partial remission (PR), stable disease (SD),
and progression disease (PD), was evaluated according to
standardized response criteria for non-Hodgkin’s lymphoma
[26]. Clinical response was evaluated after the 2nd cycle of
treatment. In case of achieving CR or PR, the patient contin-
ued with four additional cycles, and the response was evalu-
ated within 60 days after finishing the 6th cycle. Clinical
follow-up was performed every 3 months, in the first and
second year, and every 6 months in the following years.
Criteria for withdrawal of the study included no response or
PD after the 2nd cycle, partial remission after the 6th cycle,
recurrence of the lymphoma, unacceptable toxicity, or refusal
to continue with the treatment (Fig. 1). Liposomal cytarabine
(50 mg) was administered by lumbar puncture on day 1 of the
1st, 2nd, and 6th cycle of R-CHOP14. Patients also received
the concurrent administration of 4 mg dexamethasone
(intrathecal or oral). CNS involvement was assessed by
using standard CSF cytology or flow cytometry.
Procedures were performed in accordance with the
guidelines established in the Declaration of Helsinki.
Toxicity due to IT liposomal cytarabine was determined
according to Common Terminology Criteria for Adverse
Events (AEs), version 3.0. Secondary endpoints includ-
ed the evaluation of the overall survival (OS), time to
progression or relapse, and progression-free survival
(PFS). The analysis was performed using the intended-
to-treat population. Survival functions were estimated by
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using Kaplan–Meier method (95 % confidence interval,
95 % CI). All the statistical procedures were performed
using SAS 9.0.
Results
Characteristics of high-risk patients for CNS involvement
From 129 patients of the multicenter study, 24 (18.6 %) cases
presented at least one of the risk factors for CNS involvement
considered when the trial was designed. Demographic, clini-
cal characteristics, and risk factors for CNS involvement of
this subset of patients at diagnosis are shown in Table 1.
Median time from diagnosis to IT prophylaxis was 0.5 months
(IQR, 48.0–72.5).
Clinical outcomes among the 24 patients with high risk
for CNS involvement
From the 24 patients, 21 were evaluable for response 60 day
after the 6th R-CHOP, 18 patients (75 %) achieved CR and 1
(4%) PR.With a median follow-up of 40.1 months, 3 year OS
was 80.8 % (95 % CI, 63.8–97.8), and 3 year PFS was 70.7 %
(95 % CI 50.9–90.5) (Fig. 2). One patient (4.2 %) relapsed,
and three (12.5 %) patients progressed. None of the patients
experienced CNS relapse during the follow-up period. The
patient who relapsed developed a mediastinal mass. Six pa-
tients (25.0 %) died during the follow-up due to lung cancer
(n=1), pneumonia (n=1), disease progression (n=2), sepsis
by Escherichia coli (n=1), and unknown cause (n=1).
Prophylactic effect of intrathecal liposomal cytarabine
The analysis of the CSF was performed by cytology in 52
samples and by flow cytometry in 7 samples. CSF was nega-
tive for lymphoma infiltration at diagnosis in all patients.
Adverse events of liposomal cytarabine intrathecal therapy
among 70 IT infusions are shown in Table 2. A total of 18
patients (75.0 %) completed the three doses of IT liposomal
cytarabine. Causes of discontinuation were as follows: toxic-
ity (n= 1), systemic progression (n= 1), medical decision
(n=1), change to methylprednisolone treatment (n=1), or
death (2). Most of IT infusions 64/70 (91.4 %) were with
concurrent administration of dexamethasone.
Discussion
The implication of the CNS is an uncommon complication
with very poor prognosis occurring in patients with DLBCL
[7]. While the addition of rituximab to CHOP regimen has
demonstrated to improve clinical outcomes in patients with
DLBCL, its effect on CNS dissemination is unclear [27].
CNS prophylaxis has become a standard procedure recom-
mended in high-risk patients since the demonstration of reduc-
ing CNS relapse and improving survival rates [15, 16]. The
identification of risk factors at diagnosis for CNS relapse in
DLBCL patients is a controversial issue. Hollender et al. de-
scribed five risk factors in the pre-rituximab era: older than
60 years, elevated LDH, low albumin levels, two or more
extranodal involvement, and bulky retroperitoneal mass
[28]. In recent years, Schmitz et al., basing on data from the
MiNT trial, have found that the optimal risk model included
Fig. 1 Scheme of R-CHOP
cycles and evaluation times
during the study
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the combination of the involvement of more than one
extranodal site and elevated levels of LDH [29]. When the
analysis was restricted to patients receiving rituximab with
chemotherapy, the risk model included advanced stage and
elevated LDH. Savage et al. have recently confirmed the
prognostic model proposed by the German group, which in-
cludes the five risk factors of IPI in addition to kidney/adrenal
gland involvement [30, 31], in a large cohort of DLBCL pa-
tients. Furthermore, certain extranodal sites such as testis [32],
breast [33], and kidney [34] have also been considered to
increase the risk of CNS progression [35–37]. In our study,
we analyzed retrospectively the risk factors identified in the
rituximab era as shown in Table 1. Almost one third of the
patients had simultaneously advanced stage and elevated
LDH. At the time that our trial was designed, patients with
known factors for a higher risk of CNS progression were
included for CNS prophylaxis.
There are different strategies to prevent CNS lymphoma
involvement in high-risk patients. One of them consists on
high dose iv methotrexate (3.0–3.5 g/m2) alternating with che-
motherapy [38–40]. This is an effective option; however, it
can be only used in young patients due to its higher toxicity,
and it also may cause the delay of the systemic therapy. The
use of IT injections of antineoplastic drugs is another option
for CNS involvement prophylaxis. Among the different IT
prophylactic strategies, liposomal cytarabine allows maintain-
ing cytotoxic levels of the free drug in the CSF for an extended
period of time (>14 days) [19, 22]. The administration of IT
liposomal cytarabine is less frequent than conventional thera-
pies, leading to minimize the patient’s discomfort and risks
associated with lumbar puncture procedures. Randomized
clinical trials have demonstrated similar efficacy of IT liposo-
mal cytarabine as IT MTX or conventional cytarabine in pa-
tients with leptomeningeal infiltration [23, 41, 42].
Furthermore, in comparison with IT cytarabine, liposomal
cytarabine has demonstrated higher response rates and a sig-
nificant improvement in quality of life [43]. The efficacy of
liposomal cytarabine has been demonstrated in Burkitt’s lym-
phoma, acute lymphoblastic leukemia, and unclassifiable
highly aggressive B-cell lymphoma [23, 24]. However, there
are no data on patients with DLBCL for prophylactic pur-
poses. Although only 24 patients were treated in our study
with prophylactic IT liposomal cytarabine, none of them de-
veloped CNS relapse during a follow-up period of
40.1 months.
Our scheme of liposomal cytarabine administration (at 1st,
2nd, and 6th cycle of R-CHOP14) was designed to reduce half
of the injections of the standard IT therapies, and taking into
account that the risk of CNS involvement is higher during the
first cycles, when the tumor is more active, leaving the last
dose as consolidation. It has been demonstrated in this trial
that the scheme is well tolerated and safe. Clinical studies
evaluating safety of IT liposomal cytarabine in patients
with DLBCL are insufficient. Most of the safety data of
IT liposomal cytarabine have been reported in highly
pre-treated patients with CNS involvement and with oth-
er aggressive lymphoproliferative diseases, such as
Burki t t lymphoma and lymphoblas t ic leukemia .
Table 1 Demographic and clinical characteristics of the 24 patients
with risk factors for CNS involvement at diagnosis
Number Percentage
Median age (limits) 66.5 18–80












Bulky disease 7 29.2
Elevated LDH 11 45.8
Extranodal involvement 16 66.7
≥2 sites 4 16.7
Risk factors for CNS prophylaxis
Testes involvement 2 8.3
Infiltration of bone marrow (>30 %) 2 8.3
Waldeyer ring involvement 6 25.0
Retroperitoneal mass ≥10 cm 7 29.1
Bulky cervical nodes involvement 8 33.3







Schmitz/Savage criteria for risk of CNS involvement
1 factor 8 33.3
2–3 factors 12 50.0
4–6 factors 4 16.7
Other risk factors for CNS involvement
Elevated LDH and ≥2 extranodal involvement 2 8.3
Elevated LDH and Ann Arbor stage III–IV 7 29.0
Kidney/adrenal gland involvement 2 8.3
Breast involvement 0 0.0
CNS central nervous system, ECOG Eastern Cooperative Oncology
Group performance status, IPI International Prognostic Index, LDH
lactate dehydrogenase
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Commonly described AEs associated with liposomal
cytarabine include headache, nausea, fever, vomiting,
and back pain. Reported grade 3–4 AEs include
arachnoiditis, persistent lumbar pain, peripheral sensory
neuropathy, motor neuropathy, and optical nerve neuritis
[44–47]. On the other hand, one study has reported se-
vere neurotoxicity (including seizures, encephalitis,
cauda equina syndrome, or pseudotumor cerebri) associ-
ated with IT liposomal cytarabine administered concur-
rently with high-dose MTX and cytarabine in patients
with acute lymphocytic leukemia [48]. Therefore, the
concurrent administration of these drugs is contraindi-
cated. Patients in our study were receiving their first line
systemic therapy and prophylact ic IT l iposomal
cytarabine, and toxicity has been much lower, 25 % of
patients suffered IT chemotherapy related events, and
only 8.3 % suffered grade 3/4 AEs. Patients experienced
grade 1–2 headache (n = 2), dizziness (n = 1), confusion
(n = 1), and grade 3–4 headache (n = 1) and nausea/
vomiting (n = 1). In a previous study of our group,
Garcia-Marco et al. evaluated retrospectively the effica-
cy and safety of the therapeutic use of liposomal
cytarabine for the treatment of lymphomatous meningitis
in patients with lymphoma, mainly DLBCL [49]. Fifty
patients received corticosteroids for the prevention of
chemical arachnoiditis. The most commonly used agent
was dexamethasone (usually 4 mg po twice daily for
5 days with each cycle of liposomal cytarabine).
Liposomal cytarabine was well tolerated and produced
no AEs in 30 out of 54 of the patients. In the remaining
ones, headache grade 1–2 (n = 17) was the most common
AE reported, followed of nausea (n = 7), fever (n = 7),
vomiting (n = 6), neurologic deficits (n = 2), and dizzi-
ness (n = 1). By contrast with our study, one patient (re-
ceiving also dexamethasone) did have neurotoxicity.
Recently, Krawczyk et al. also determined efficacy and
safety of liposomal cytarabine as CNS prophylaxis in
patients with DLBCL [50]. All patients received oral
prednisone (as an element of the R-CHOP regimen) on
administration of intrathecal liposomal cytarabine. In
their study, 59 out of 79 patients (74.7 %) experienced
AEs, mainly headache. Other AEs were nausea (n=13), fever
(n= 10), vomiting (n= 5), dizziness (n = 3), neurological
deficits (n=3), and myelopathy (n=1). The rate of AEs was
higher than in our study, as seven patients suffered grade 3–4.
In another study of our group, 54 patients with lymphoma
(25 DLBCL) received prophylactic IT cytarabine with 4 mg
IT dexamethasone and 20 mg iv dexamethasone on day 1,
and only 4 (3.5 %) grade 3 AEs among 112 administrations
were observed. Therefore, it seems that the concurrent admin-
istration of dexamethasone can avoid the development of
chemical arachnoiditis [51]. The main limitation of the pres-
ent study was the low number of high-risk patients available
in the original trial. Nevertheless, it is important to highlight
that our results are derived from a prospective study defined
by a homogeneous systemic treatment in all the patients.
Fig. 2 Analysis of the overall
survival, time to progression/
relapse, and progression-free
survival achieved by R-CHOP
treatment
Table 2 Adverse events of 70 liposomal cytarabine IT infusions for
CNS prophylaxis
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In conclusion, IT liposomal cytarabine has demonstrated
being safe, feasible, and effective for CNS prophylaxis, caus-
ing few associated risks and little discomfort to patients with
DLBCL.
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